The Payer's Playbook: Ampa’s Bid to Make Brain Tech a Covered Benefit

PALO ALTO, CA – June 23, 2026 – In the world of corporate announcements, the appointment of an advisor can often feel like a footnote. But when neurotechnology startup Ampa announced today that Dr. Doug Nemecek, the former Chief Medical Officer of Behavioral Health at The Cigna Group, was joining its team, it signaled something far more significant. This isn't just another hire; it's a meticulously calculated move in a high-stakes game to solve one of the biggest puzzles in modern healthcare: getting insurance companies to pay for revolutionary treatments.

For years, the story of mental healthcare innovation has followed a frustrating pattern: a promising new therapy emerges, but it remains inaccessible to the vast majority of patients, trapped behind a wall of high costs and restrictive insurance policies. Ampa, with its portable brain-stimulation device for depression, is betting that the key to tearing down that wall isn't just better technology, but a better understanding of the people who hold the purse strings. By bringing a two-decade insurance veteran into the fold, the company is making a clear statement: the path to mainstream adoption runs directly through the payer’s office.

Cracking the Payer Code

To understand the weight of this announcement, you have to understand who Dr. Doug Nemecek is. For more than 20 years at Cigna, he wasn’t just a physician; he was a key architect of strategy for a multibillion-dollar behavioral health business covering over 16 million people. His role involved shaping the very policies that determine what treatments get covered and for whom. He has spent his career on the other side of the table, evaluating new therapies and designing networks with a sharp eye on two things: clinical outcomes and cost-effectiveness.

"Doug has spent his career shaping how behavioral health care is evaluated, delivered, and reimbursed," said Don Vaughn, Ph.D., CEO of Ampa, in the company’s press release. That experience is precisely what makes him invaluable. In his advisory role, Dr. Nemecek will help Ampa generate the specific "outcomes evidence" that health plans rely on to establish what the industry calls "durable coverage pathways." In simpler terms, he knows exactly what data and proof points a company like Cigna needs to see before it will consistently approve and pay for a new treatment like transcranial magnetic stimulation (TMS).

Dr. Nemecek himself echoed this focus on proven value. "The future of behavioral health care depends on delivering consistent, high-quality treatment that demonstrates meaningful outcomes, while aligning incentives across clinicians, patients, and payers," he stated. His move to advise Ampa suggests he sees the potential for the company's technology to meet this high bar.

A New Prescription for an Old Problem

Transcranial magnetic stimulation, or TMS, is not new. The FDA first cleared it for treatment-resistant depression in 2008. The non-invasive therapy uses magnetic fields to stimulate nerve cells in the brain, offering hope to patients for whom antidepressants have failed. Yet, despite its proven efficacy, TMS has remained a niche treatment. The reason lies in the numbers. Traditional TMS machines are bulky, complex, and can cost a small fortune, making them a prohibitive investment for many clinics.

Furthermore, the treatment regimen itself has been a major logistical hurdle. A standard course of TMS often requires patients to visit a clinic for daily sessions, five days a week, for up to eight weeks. This grueling schedule is simply impossible for many people juggling jobs, family, and the very depression the treatment aims to alleviate.

This is the landscape Ampa aims to disrupt with its flagship product, Ampa One. The company has re-imagined the TMS device from the ground up, creating a system that is portable enough to fit in a car trunk, simple enough to operate with minimal training, and offered on an affordable subscription model reported to be a fraction of the cost of legacy equipment. One industry insider called it "the iPhone of the field," a device poised to make a complex technology accessible and scalable.

But the most significant innovation may be the "Ampa One Day protocol." Early data from clinical sites using the device suggests a full course of treatment can be condensed into a single day, with a reported 70% of patients achieving remission. If these results hold up in larger studies, it would represent a monumental shift, transforming a weeks-long ordeal into a one-day, outpatient procedure.

The Data-Driven Path to Mental Wellness

Ampa’s strategy aligns perfectly with a powerful undercurrent in healthcare: the shift from paying for services to paying for results. This "value-based care" model is gaining momentum, as insurers and employers are no longer content to simply pay for appointments and prescriptions; they want to pay for what works. In mental health, however, this has been a challenge. How do you consistently measure a "meaningful outcome"?

This is where Ampa’s focus on being "measurable" and "outcomes-oriented" becomes more than just marketing jargon. The Ampa One system is designed with features like camera-guided targeting to ensure the magnetic pulses are delivered to the precise location every time. This consistency is critical for generating reliable data. By building a connected device that tracks treatment delivery and quality, Ampa is creating a platform to prove its effectiveness on a patient-by-patient basis.

This data is the currency of modern healthcare. For a payer, having clear evidence that a one-day, $X-thousand procedure leads to a high rate of remission—potentially avoiding years of costly medication, therapy, and lost productivity—makes for a compelling economic argument. Ampa isn't just selling a device; it's selling a verifiable outcome, packaged in a way that directly appeals to the data-driven mindset of an executive like Dr. Nemecek.

From Niche Treatment to Mainstream Care

Since emerging from stealth mode in late 2025 with FDA clearance and an $8.5 million funding round, Ampa has moved at a blistering pace. The company has since raised its total funding to over $25 million from high-profile investors and has already rolled out its Ampa One system to clinics in more than 30 states. The ambition is clear, encapsulated in the company's bold vision: "one billion remissions."

By hiring Dr. Nemecek, Ampa is acknowledging a fundamental truth of health-tech innovation. The most brilliant device is useless if no one can access it. The biggest hurdles are often not technological but bureaucratic and economic. Ampa’s three-pronged strategy—a radically accessible device, a data-driven approach to prove its value, and now, an insider’s playbook to navigate the world of insurance reimbursement—is a comprehensive assault on those barriers. This appointment signals that the company is not just building a better machine, but also building the bridge that will carry it into the mainstream of mental healthcare.